Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2018 Earnings Results

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 11.86%

Alnylam Pharmaceuticals reported a wider-than-expected loss per share, leading to a significant drop in stock price. The lack of revenue figures and guidance left investors uncertain about the company's immediate future. The stock's decline reflects market concerns over ongoing challenges and the absence of clear direction from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.56	N/A	+16.70%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about market conditions affecting performance. They reiterated their commitment to long-term goals.

Management highlighted ongoing challenges in the market.

They emphasized a focus on long-term strategies despite current setbacks.

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 11.86%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 11.86%

Key numbers

Management commentary